Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Nuvalent, Inc.
  6. Summary
    NUVL   US6707031075

NUVALENT, INC.

(NUVL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
26.6(c) 26.07(c) 22.86(c) 23.74(c) 22.645 Last
166 167 98 741 144 915 210 721 13 159 Volume
-19.86% -1.99% -12.31% +3.85% -4.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -42,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -15,4x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -97,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,8x
Yield 2022 -
Capitalization 1 146 M 1 146 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 27
Free-Float 83,6%
More Financials
Company
Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS1 and ALK kinases, along with multiple discovery-stage research programs. The Company's pipeline includes NVL-520 and NVL-655. NVL-520, is a... 
More about the company
All news about NUVALENT, INC.
09/20NUVALENT, INC.(NASDAQGS : NUVL) added to S&P TMI Index
CI
09/08NUVALENT : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
09/08NUVALENT : Net Loss Widens as Operating Expenses More Than Double in Q2
MT
09/08NUVALENT, INC. : Results of Operations and Financial Condition, Financial Statements and E..
AQ
09/08Nuvalent, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Mont..
CI
08/23NUVALENT : JPMorgan Starts Nuvalent at Overweight With $34 Price Target
MT
08/23NUVALENT : Cowen Initiates Coverage on Nuvalent With Outperform Rating
MT
08/23NUVALENT : Piper Sandler Starts Nuvalent at Overweight With $40 Price Target
MT
08/02NUVALENT : Announces Closing of Upsized Initial Public Offering
PR
08/02NUVALENT, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia..
AQ
07/30NUVALENT, INC.(NASDAQGS : NUVL) added to NASDAQ Composite Index
CI
07/28NUVALENT : Announces Pricing of Initial Public Offering
PR
07/28Nuvalent, Inc. has completed an IPO in the amount of $165.75 million.
CI
07/06Nuvalent, Inc. has filed an IPO in the amount of $100 million.
CI
01/27Nuvalent, Inc. announced that it has received $52.23494 million in funding from Deerfie..
CI
More news
News in other languages on NUVALENT, INC.
09/08La perte nette de Nuvalent se creuse alors que les dépenses d'exploitation ont plus que..
More news
Analyst Recommendations on NUVALENT, INC.
More recommendations
Chart NUVALENT, INC.
Duration : Period :
Nuvalent, Inc. Technical Analysis Chart | NUVL | US6707031075 | MarketScreener
Technical analysis trends NUVALENT, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 23,74 $
Average target price 38,50 $
Spread / Average Target 62,2%
EPS Revisions
Managers and Directors
James R. Porter President, Chief Executive Officer & Director
Alexandra Balcom Chief Financial Officer
Cameron Wheeler Chairman
Christopher D. Turner Chief Medical Officer
Robert Bowers Jackson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NUVALENT, INC.0.00%1 146
MODERNA, INC.291.35%165 027
LONZA GROUP AG26.86%57 923
IQVIA HOLDINGS INC.38.49%47 547
CELLTRION, INC.-25.49%31 003
SEAGEN INC.-7.21%29 566